A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi(™), ENF) plus binimetinib (Mektovi(®), BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Patients treated with com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefnawy, Mohamed M., Alanazi, Mohammed M., Al-Hossaini, Abdullah M., Alnasser, Abdulaziz I., El-Azab, Adel S., Jardan, Yousef A. Bin, Attwa, Mohamed W., El-Gendy, Manal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822280/
https://www.ncbi.nlm.nih.gov/pubmed/36615272
http://dx.doi.org/10.3390/molecules28010079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822280/
https://www.ncbi.nlm.nih.gov/pubmed/36615272
http://dx.doi.org/10.3390/molecules28010079

Ejemplares similares